Quote:
Originally Posted by 46zilzal
This is an NIH article....COMPETENCE personified
|
The article below is published on the NIH.gov site.
Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414075/
Quote:
ABSTRACT
This study focuses on cardiovascular manifestation, particularly myocarditis and pericarditis events, after BNT162b2 mRNA COVID-19 vaccine injection in Thai adolescents. This prospective cohort study enrolled students aged 13–18 years from two schools, who received the second dose of the BNT162b2 mRNA COVID-19 vaccine. Data including demographics, symptoms, vital signs, ECG, echocardiography, and cardiac enzymes were collected at baseline, Day 3, Day 7, and Day 14 (optional) using case record forms. We enrolled 314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis. The most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). One participant could have more than one sign and/or symptom. Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments. Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis. In conclusion, Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis. The clinical presentation of myopericarditis after vaccination was usually mild and temporary, with all cases fully recovering within 14 days. Hence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects. Clinical Trial Registration: NCT05288231.
|
Quote:
2.3. Definition of Cardiovascular Manifestation
In this study, cardiovascular manifestation was defined as one or more of the following:
- Chest pain/pericarditis
- Dyspnea/orthopnea
- Palpitation
- Hypertension/hypotension
- Tachycardia/bradycardia
- Shock/cardiogenic shock
- Abnormal ECG or abnormal rhythm or ECG change
- Bundle branch block
- Decreased ejection fraction
- Diastolic dysfunction
- Elevation in at least one cardiac biomarker (troponin-T, CK-MB)/myocarditis
|
In this study, 301 kids from two schools were examined by cardiologists after their second mRNA dose:
29 percent of the kids in the study were diagnosed with a "cardiovascular manifestation."
One kid was diagnosed with Myopericarditis.
Two kids had suspected Pericarditis.
Four kids had suspected Subclinical Myocarditis.
All of the kids diagnosed with a cardiovascular manifestation were treated by cardiologists, and all resolved.
There are other studies like this with similar results.
To the best of my knowledge no studies like this (where everyone was examined by cardiologists after mRNA vaccination) have been funded in the US.
Ask yourself "What if?"
What if even 1% of young people (instead of 29% from the study) develop cardiovascular manifestations after mRNA vaccination?
How many of those 1% are being examined by cardiologists?
None.
How many of those of those 1% go on to develop Myocarditis, feel just a little "off" because they're young, and don't seek treatment until it's too late?
The answer isn't zero.
-jp
.
